Fasting or the short‐term consumption of a ketogenic diet protects against antipsychotic‐induced hyperglycaemia in mice

摘要

Abstract Antipsychotic (AP) medications, such as olanzapine (OLZ), are used in the treatment of schizophrenia and a growing number of ‘off‐label’ conditions. A single dose of OLZ causes robust increases in blood glucose within minutes of treatment. The purpose of the current study was to investigate whether interventions that increase circulating ketone bodies (fasting, β‐hydroxybutyrate (βHB), ketone esters or a ketogenic diet (KD)) would be sufficient to protect against the acute metabolic side effects of OLZ. We demonstrate that fasting or the short‐term consumption of a KD protects against OLZ‐induced hyperglycaemia, independent of alterations in whole‐body insulin action, and in parallel with a blunted rise in serum glucagon. Interestingly, the effects of fasting and KDs were not recapitulated by acutely increasing circulating concentrations of ketone bodies through treatment with βHB or oral ketone esters, approaches which increase ketone bodies to physiological or supra‐physiological levels, respectively. Collectively, our findings demonstrate that fasting and the short‐term consumption of a KD can protect against acute AP‐induced perturbations in glucose homeostasis, whereas manipulations which acutely increase circulating ketone bodies do not elicit the same beneficial effects. Key points Antipsychotic medications cause rapid and robust increases in blood glucose. Co‐treatment approaches to offset these harmful metabolic side effects have not been identified. We demonstrate that fasting or the consumption of a short‐term ketogenic diet, but not treatment with β‐hydroxybutyrate or oral ketone esters, protects against acute antipsychotic‐induced hyperglycaemia. The protective effects of fasting and ketogenic diets were paralleled by reductions in serum glucagon, but not improvements in whole‐body insulin action.